ArticleScientific reports2025
Design and fabrication of a mesoporous silica scaffold for oral delivery of peptides.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of this effort was to create mesoporous nanoparticles (MSNs) decorated with amine groups and loaded with liraglutide (LRT) for oral delivery. Amine-decorated MSNs were helpful for peptide entrapment and prolonged release of liraglutide, a GLP-1 analog. Liraglutide-loaded MSNs were made by using acetonitrile and water sol-gel techniques. Over the course of 24 h, the particles provided consistent drug release, with cumulative release reaching up to 90% in vitro. Differential dynamic light scattering, scanning electron microscopy (SEM), Fourier transform infrared (FTIR) spectroscopy, Brunauer-Emmett-Teller (BET) analysis and differential scanning calorimetry (DSC) were used to characterize the synthesized formulation. The MTT assay was used to evaluate cell viability along with the hemolysis assay and was found to be safe. Particle size determination was performed by a zeta sizer; the size was 286 nm [Formula: see text], and the PDI and zeta potential were 0.29 and +8.89 mV, respectively. The drug entrapment efficiency was also very good at 56% ± 9%, and the drug release was more than 90.0% ± 9 within 24 h at all pH values tested. The efficacy of the particles was examined in a rat model of diabetes and contrasted with that of a group that received daily injections of liraglutide. Between 0 and 5 days after the start of treatment, lower blood sugar levels were observed in the particle treatment groups than in the injection groups. Overall, the liraglutide-loaded MSNs created in this work are effective in a rat model of diabetes, and as a result, we believe that they have great potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.